Demographic representation in Phase III clinical trials of anti‐amyloid therapy for Alzheimer’s disease: a cross‐sectional analysis

Abstract

Background: Alzheimer’s disease (AD) is known to vary in prevalence amongst different ethnic and racial groups. Phase III clinical trials set the standard for safety and efficacy of new medicinal therapies.

The paper